SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is fueling a market-wide relief rally after reporting robust Azure cloud growth that suggests its heavy AI investments are successfully driving revenue. The community is focused on the stock's role as a market stabilizer following disappointing results from other tech giants, with investors closely watching for a short squeeze as many traders move to cover bearish positions.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following the UAE's broad regulatory approval of ANKTIVA for bladder and lung cancer treatments, marking a significant expansion of its global footprint. While retail sentiment remains optimistic due to strong revenue projections and potential upcoming earnings catalysts, the stock continues to face intense volatility driven by high short interest and speculative community discussions surrounding potential global partnerships.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line Holdings Ltd is facing downward pressure as investors digest mixed signals regarding the company's forward-looking profit margins and cash-flow projections. Community members are actively debating the stock's long-term turnaround potential versus short-term volatility, with many monitoring fuel costs and broader sector sentiment as key indicators.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya is trending as investors react to a series of record-breaking asset-backed securitization deals, with the community closely tracking the stock's potential for a technical breakout amid favorable analyst ratings. Sentiment remains divided between bullish enthusiasm over the company's AI-driven fintech expansion and concerns regarding the broader macroeconomic impact of interest rates and geopolitical risks.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as investors grapple with escalating geopolitical tensions in the Middle East and rising Treasury yields, which are fueling concerns about long-term debt sustainability and inflation. The community is actively debating whether the iShares 20+ Year Treasury Bond ETF offers a legitimate flight-to-safety opportunity amid equity volatility or if it remains a value trap in a high-rate environment.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing significant selling pressure as investors react to elevated capital expenditure plans for AI infrastructure and a guidance miss that highlights near-term profitability concerns. The community is actively debating whether Meta's aggressive investment in compute and AI capabilities will eventually yield scalable monetization or if the company is entering a period of prolonged margin compression.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to anticipation surrounding the upcoming maintenance dosing data for VK2735, which is widely viewed by investors as a critical catalyst for validating the drug's commercial potential. The community is actively discussing the stock's long-term competitive positioning within the obesity market, balancing excitement over strong clinical progress with concerns regarding management's communication, cash burn, and the potential for future equity dilution.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood investors are closely monitoring upcoming earnings as the stock experiences heightened volatility, with the community split between concerns over potential downside and optimism regarding new revenue streams like prediction markets and banking. Despite recent price pullbacks and analyst price target adjustments, bullish sentiment remains centered on the company's product velocity and potential for long-term growth as a diversified fintech platform.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is currently trending as investors brace for its upcoming earnings, with high-stakes scrutiny on whether AWS cloud growth can justify the company's aggressive AI infrastructure capital expenditures. The stock is also gaining attention following news of a proposed massive satellite constellation, while market sentiment remains divided between long-term confidence in its AWS-driven profitability and short-term volatility concerns linked to sector-wide spending patterns.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry Ltd is currently trending as shareholders express heightened volatility and frustration over a significant price retracement, with community sentiment split between long-term confidence in QNX software partnerships and accusations of mismanagement following recent insider share sales. Investors are actively debating the company's capital allocation and the timing of anticipated enterprise announcements, which remain a primary focus for those looking for a potential reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  Concentra Group Holdings Parent, Inc. (CON) This Year?

Here is how Concentra Group (CON) and Cytokinetics (CYTK) have performed compared to their sector so far this year.

All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy

Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet

The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

What This Cytokinetics Insider Sale Might Mean With the Stock Up 110%

Key PointsThe insider liquidated 7,500 shares at a weighted average price of $82.02...

Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure?

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

Cytokinetics Gains 18.4% Year to Date: How to Play the Stock?

CYTK has gained 18.4% YTD as Myqorzo's FDA approval, early launch momentum, and expanding market opportunities fuel investor interest.

Can BMY's Camzyos Strengthen Its Cardiovascular Portfolio?

Bristol Myers eyes growth from Camzyos as the FDA reviews its use in adolescents with obstructive HCM, expanding the drug's market reach.

Top Analyst Reports for Costco, Lam Research & KLA

Costco, Lam Research and KLA headline Zacks' top analyst reports, with AI demand, digital investments and expansion plans driving focus.

Why Is Cytokinetics (CYTK) Down 5.5% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch

Cytokinetics posts Q1 loss as Myqorzo launch lifts revenues to $19.4M, signaling commercial shift amid rising SG&A tied to rollout and expansion.

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics?

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$1.63	--	--	N/A
Q1 '26	-$1.65	-$1.67	-1.07%	MISSED
Q4 '25	-$1.56	-$1.50	4.12%	BEAT
Q3 '25	-$1.57	-$2.55	-62.36%	MISSED
Q2 '25	-$1.43	-$1.12	21.66%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CYTKCytokinetics Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CYTK News